OAC
OVID icon

OMERS Administration Corp’s Ovid Therapeutics OVID Stock Holding History

OMERS Administration Corp’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-100,100
Closed -$222K – 1077
2026
Q1 		$222K Sell
100,100
-25,200
-20% -$45.1K ﹤0.01% 894
2025
Q4 		$204K Buy
+125,300
New +$193K ﹤0.01% 912

Other funds holding OVID

JT
Jupiter Topco New York $245B AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

OMERS Administration Corp's OVID Position: Q2 2026 in Review

OMERS Administration Corp sold out of Ovid Therapeutics (OVID) in Q2 2026, closing a stake of 100,100 shares — an estimated $222K sold.

OMERS Administration Corp first reported a position in OVID in Q4 2025 and held it in 2 quarters. The position peaked at $222K in Q1 2026. 131 funds tracked by Wall St. Rank hold OVID as of Q2 2026.

  • OMERS Administration Corp reported no remaining Ovid Therapeutics position as of Q2 2026 after selling out during the quarter.
  • OMERS Administration Corp sold 100,100 Ovid Therapeutics shares in Q2 2026, an estimated $222K.
  • OMERS Administration Corp first reported a position in Ovid Therapeutics in Q4 2025 and held it in 2 quarters.
  • OMERS Administration Corp's Ovid Therapeutics position peaked at $222K in Q1 2026.
  • 131 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.

Based on OMERS Administration Corp's 13F filing for Q2 2026, filed 13 Aug 2026.